References
- Filipsson S, Hultén L, Lindstedt G. Malabsorption of fat and vitamin B12 before and after intestinal resection for Crohn's disease. Scand J Gastroenterol 1978; 13: 529–536
- Hildell J, Lindstrom C, Wenckert A. Radiographic appearances in Crohn's disease. Acta Radiol Diagn 1979; 20: 609–625
- Garlock J, Crohn B. An appraisal of the results of surgery in the treatment of regional ileitis. JAMA 1945; 127: 205
- Dyson W L, Hodes P J. Rhoads JE. Late results in the surgical treatment of regional enteritis. Pa Med 1954; 57: 433–438
- Davis J. The prognosis of Crohn's disease. Postgrad Med J 1961; 37: 783
- Schölmerich J, Schmidt E, Schümichen C, Billmann P, Schmidt H, Gerok W. Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label. Gastroenterology 1988; 95: 1287–93
- Bjarnason I, Zanelli G, Smith T. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987; 93: 480–89
- Steinfeld J, Davidson J, Gordon R, Greene F. The mechanism of hypoproteinemia in patients with regional enteritis and ulcerative colitis. Am J Med 1960; 29: 405–415
- Jarnum S, Jensen K B. Fecal radioiodine excretion following intravenous injection of 131I-albumin and 125I-immunoglobulin G in chronic inflammatory bowel disease. Gastroenterology 1975; 68: 1433–1444
- Beeken W L, Busch H J, Sylwester D L. Intestinal protein loss in Crohn's disease. Gastroenterology 1972; 62: 207–215
- Fasth S, Hellberg R, Hultén L, Magnusson O. Early complications after surgical treatment for Crohn's disease with particular reference to factors affecting their development. Acta Chir Scand 1980; 146: 519–526
- Morson B C. Crohn's disease. Proc Roy Soc Med 1968; 61: 79–81
- Rootwelt K. Direct intravenous injection of 51chromic chloride compared with l25I-polyvinyl-pyrrolidone and 131I-albumin in the detection of gastrointestinal protein loss. Scand J Clin Lab Invest 1966; 18: 405–416
- Sköldborn H., Arvidsson B, Andersson M. A new whole body monitoring laboratory. Acta Radiol 1972; 233–241, suppl 313
- Walker-Smith J A, Skyring A P, Mistilis S P. Use of 51CrCl3 in the diagnosis of protein-losing enteropathy. Gut 1967; 8: 166–168
- Jarnum S, Westergaard H, Yssing M, Jensen H. Quantitation of gastrointestinal protein loss by means of Fe59-labeled iron dextran. Gastroenterology 1968; 55: 229–241
- Eustace P W, Gaunt J I. Croft DN. Incidence of protein-losing enteropathy in primary lympho-edema using chromium-51 chloride technique. Br Med J 1975; 4: 737
- Kinmonth J B, Eustace P W. Gut protein loss in lymphoedema. Proc Roy Soc Med 1975; 68: 673–675
- Da Costa L R, Croft D N, Creamer B. Protein loss and cell loss from the small-intestinal mucosa. Gut 1971; 12: 179–183
- Gordon R, Jr. Exudative enteropathy: Abnormal permeability of the gastrointestinal tract demonstrable with labelled polyvinyl pyrrolidone. Lancet 1959; 1: 325
- Jarnum S. The 131-polyvinylpyrrolidone (131I-PVP) test in gastrointestinal protein loss. Scand J Clin Lab Invest 1961; 13: 447–461
- Waldmann T A. Gastrointestinal protein loss demonstrated by 51Cr-labelled albumin. Lancet 1961; 2: 121–123
- Waldmann T A. Protein-losing enteropathy and kinetic studies of plasma protein metabolism. Semin Nucl Med 1972; 2: 251–264
- Karbach U, Ewe K, Dehos K. Antiinflammatory treatment and intestinal cr-1-antitrypsin clearance in active Crohn's disease. Dig Dis Sci 1985; 30: 229–235
- Van Tongeren J H, Eekhout A L. Criteria to assess the severity of Crohn's disease and the effect of treatment. The management of Crohn's disease, I T. Weterman, A S. Peña, C C. Booth. Exerpta Medica, Amsterdam 1976; 153–160